Loading…
Lobbying Spend
—
Filings
9
Firms Hired
2
Active Period
2015–2016
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
Strengthening Medicare Advantage through Innovation and Transparency for Seniors of 2015
2016 · second_quarter · Firm: THE NICKLES GROUP, LLC
H.R. 2570, Strengthening Medicare Advantage through Innovation and Transparency for Seniors; S. 275 / H.R. 605, the Medicare Home Infusion Site of Care Act of 2015 and issues related to reimbursement for infused drugs administered through DME. Issues related to pharmaceutical prices, including the Part B Demonstration.
Client expense: — · Firm income: $52,500
Matched citations: H.R. 2570
H.R. 6, The 21st Century Cures Act and the Innovations Initiative. S. 1878, Advancing Hope Act of 2016, concerning extension of the pediatric priority review voucher program. Issues concerning care for chronic disease patients.
Client expense: — · Firm income: $52,500
Matched citations: H.R. 6
Medicare Home Infusion Site of Care Act of 2015
2016 · second_quarter · Firm: THE NICKLES GROUP, LLC
H.R. 2570, Strengthening Medicare Advantage through Innovation and Transparency for Seniors; S. 275 / H.R. 605, the Medicare Home Infusion Site of Care Act of 2015 and issues related to reimbursement for infused drugs administered through DME. Issues related to pharmaceutical prices, including the Part B Demonstration.
Client expense: — · Firm income: $52,500
Matched citations: H.R. 605
H.R. 6, The 21st Century Cures Act and the Innovations Initiative. S. 1878, Advancing Hope Act of 2016, concerning extension of the pediatric priority review voucher program. Issues concerning care for chronic disease patients.
Client expense: — · Firm income: $52,500
Matched citations: S. 1878
Puerto Rico Oversight, Management, and Economic Stability Act
2016 · second_quarter · Firm: THE NICKLES GROUP, LLC
Issues related to corporate tax reform and the taxation of U.S. multinational corporations. Issues related to corporate mergers. Monitored issues related to the Treasury Department's proposed Sect. 385 regulations. Monitored issues related to S. 2328, PROMESA.
Client expense: — · Firm income: $52,500
Matched citations: S. 2328
Medicare Home Infusion Site of Care Act of 2015
2016 · second_quarter · Firm: THE NICKLES GROUP, LLC
H.R. 2570, Strengthening Medicare Advantage through Innovation and Transparency for Seniors; S. 275 / H.R. 605, the Medicare Home Infusion Site of Care Act of 2015 and issues related to reimbursement for infused drugs administered through DME. Issues related to pharmaceutical prices, including the Part B Demonstration.
Client expense: — · Firm income: $52,500
Matched citations: S. 275
Strengthening Medicare Advantage through Innovation and Transparency for Seniors of 2015
2016 · first_quarter · Firm: THE NICKLES GROUP, LLC
H.R. 2570, Strengthening Medicare Advantage through Innovation and Transparency for Seniors; S. 275 / H.R. 605, the Medicare Home Infusion Site of Care Act of 2015 and issues related to reimbursement for infused drugs administered through DME. Issues related to pharmaceutical prices, including the Part B Demonstration.
Client expense: — · Firm income: $52,500
Matched citations: H.R. 2570
H.R. 6, The 21st Century Cures Act and the Innovations Initiative. Issues concerning care for chronic disease patients.
Client expense: — · Firm income: $52,500
Matched citations: H.R. 6
Medicare Home Infusion Site of Care Act of 2015
2016 · first_quarter · Firm: THE NICKLES GROUP, LLC
H.R. 2570, Strengthening Medicare Advantage through Innovation and Transparency for Seniors; S. 275 / H.R. 605, the Medicare Home Infusion Site of Care Act of 2015 and issues related to reimbursement for infused drugs administered through DME. Issues related to pharmaceutical prices, including the Part B Demonstration.
Client expense: — · Firm income: $52,500
Matched citations: H.R. 605
Medicare Home Infusion Site of Care Act of 2015
2016 · first_quarter · Firm: THE NICKLES GROUP, LLC
H.R. 2570, Strengthening Medicare Advantage through Innovation and Transparency for Seniors; S. 275 / H.R. 605, the Medicare Home Infusion Site of Care Act of 2015 and issues related to reimbursement for infused drugs administered through DME. Issues related to pharmaceutical prices, including the Part B Demonstration.
Client expense: — · Firm income: $52,500
Matched citations: S. 275
Bipartisan Budget Act of 2015
2015 · fourth_quarter · Firm: THE NICKLES GROUP, LLC
H.R. 3762, Restoring Americans' Healthcare Freedom Reconciliation Act of 2015, as it relates to the repeal of the medical device tax. H.R. 2029, Consolidated Appropriations Act, 2016, as it relates to the delay repeal of the medical device tax and reimbursement for infused drugs administered through DME. H.R. 1314, Bipartisan Budget Act of 2015.
Client expense: — · Firm income: $28,750
Matched citations: H.R. 1314
Protect Medical Innovation Act of 2015
2015 · fourth_quarter · Firm: THE NICKLES GROUP, LLC
Issues related to corporate tax reform and the taxation of U.S. multinational corporations. S. 149, the Medical Device Access and Innovation Protection Act and H.R. 160, the Protect Medical Innovation Act, and issues related to repeal of the medical device tax. S. 1946, the Tax Relief Extension Act of 2015; H.R. 34, the Tax Increase Prevention and Real Estate Investment Act of 2015; H.R. 2029, Consolidated Appropriations Act, 2016, as they relate to the R&D credit, bonus depreciation, the CFC look-through rule and the medical device tax. Issues related to corporate mergers.
Client expense: — · Firm income: $28,750
Matched citations: H.R. 160
Consolidated Appropriations Act, 2016
2015 · fourth_quarter · Firm: THE NICKLES GROUP, LLC
Issues related to corporate tax reform and the taxation of U.S. multinational corporations. S. 149, the Medical Device Access and Innovation Protection Act and H.R. 160, the Protect Medical Innovation Act, and issues related to repeal of the medical device tax. S. 1946, the Tax Relief Extension Act of 2015; H.R. 34, the Tax Increase Prevention and Real Estate Investment Act of 2015; H.R. 2029, Consolidated Appropriations Act, 2016, as they relate to the R&D credit, bonus depreciation, the CFC look-through rule and the medical device tax. Issues related to corporate mergers.
Client expense: — · Firm income: $28,750
Matched citations: H.R. 2029
Consolidated Appropriations Act, 2016
2015 · fourth_quarter · Firm: THE NICKLES GROUP, LLC
H.R. 3762, Restoring Americans' Healthcare Freedom Reconciliation Act of 2015, as it relates to the repeal of the medical device tax. H.R. 2029, Consolidated Appropriations Act, 2016, as it relates to the delay repeal of the medical device tax and reimbursement for infused drugs administered through DME. H.R. 1314, Bipartisan Budget Act of 2015.
Client expense: — · Firm income: $28,750
Matched citations: H.R. 2029
Strengthening Medicare Advantage through Innovation and Transparency for Seniors of 2015
2015 · fourth_quarter · Firm: THE NICKLES GROUP, LLC
H.R. 2570, Strengthening Medicare Advantage through Innovation and Transparency for Seniors; S. 275 / H.R. 605, the Medicare Home Infusion Site of Care Act of 2015 and issues related to reimbursement for infused drugs administered through DME.
Client expense: — · Firm income: $28,750
Matched citations: H.R. 2570
Issues related to corporate tax reform and the taxation of U.S. multinational corporations. S. 149, the Medical Device Access and Innovation Protection Act and H.R. 160, the Protect Medical Innovation Act, and issues related to repeal of the medical device tax. S. 1946, the Tax Relief Extension Act of 2015; H.R. 34, the Tax Increase Prevention and Real Estate Investment Act of 2015; H.R. 2029, Consolidated Appropriations Act, 2016, as they relate to the R&D credit, bonus depreciation, the CFC look-through rule and the medical device tax. Issues related to corporate mergers.
Client expense: — · Firm income: $28,750
Matched citations: H.R. 34
To provide for reconciliation pursuant to section 2002 of the concurrent resolution on the budget for fiscal year 2016.
2015 · fourth_quarter · Firm: THE NICKLES GROUP, LLC
H.R. 3762, Restoring Americans' Healthcare Freedom Reconciliation Act of 2015, as it relates to the repeal of the medical device tax. H.R. 2029, Consolidated Appropriations Act, 2016, as it relates to the delay repeal of the medical device tax and reimbursement for infused drugs administered through DME. H.R. 1314, Bipartisan Budget Act of 2015.
Client expense: — · Firm income: $28,750
Matched citations: H.R. 3762
H.R. 6, The 21st Century Cures Act and the Innovations Initiative. Issues concerning care for chronic disease patients.
Client expense: — · Firm income: $28,750
Matched citations: H.R. 6
Medicare Home Infusion Site of Care Act of 2015
2015 · fourth_quarter · Firm: THE NICKLES GROUP, LLC
H.R. 2570, Strengthening Medicare Advantage through Innovation and Transparency for Seniors; S. 275 / H.R. 605, the Medicare Home Infusion Site of Care Act of 2015 and issues related to reimbursement for infused drugs administered through DME.
Client expense: — · Firm income: $28,750
Matched citations: H.R. 605
Medical Device Access and Innovation Protection Act
2015 · fourth_quarter · Firm: THE NICKLES GROUP, LLC
Issues related to corporate tax reform and the taxation of U.S. multinational corporations. S. 149, the Medical Device Access and Innovation Protection Act and H.R. 160, the Protect Medical Innovation Act, and issues related to repeal of the medical device tax. S. 1946, the Tax Relief Extension Act of 2015; H.R. 34, the Tax Increase Prevention and Real Estate Investment Act of 2015; H.R. 2029, Consolidated Appropriations Act, 2016, as they relate to the R&D credit, bonus depreciation, the CFC look-through rule and the medical device tax. Issues related to corporate mergers.
Client expense: — · Firm income: $28,750
Matched citations: S. 149
Tax Relief Extension Act of 2015
2015 · fourth_quarter · Firm: THE NICKLES GROUP, LLC
Issues related to corporate tax reform and the taxation of U.S. multinational corporations. S. 149, the Medical Device Access and Innovation Protection Act and H.R. 160, the Protect Medical Innovation Act, and issues related to repeal of the medical device tax. S. 1946, the Tax Relief Extension Act of 2015; H.R. 34, the Tax Increase Prevention and Real Estate Investment Act of 2015; H.R. 2029, Consolidated Appropriations Act, 2016, as they relate to the R&D credit, bonus depreciation, the CFC look-through rule and the medical device tax. Issues related to corporate mergers.
Client expense: — · Firm income: $28,750
Matched citations: S. 1946
Medicare Home Infusion Site of Care Act of 2015
2015 · fourth_quarter · Firm: THE NICKLES GROUP, LLC
H.R. 2570, Strengthening Medicare Advantage through Innovation and Transparency for Seniors; S. 275 / H.R. 605, the Medicare Home Infusion Site of Care Act of 2015 and issues related to reimbursement for infused drugs administered through DME.
Client expense: — · Firm income: $28,750
Matched citations: S. 275
Permanent CFC Look-Through Act of 2015
2015 · third_quarter · Firm: THE NICKLES GROUP, LLC
Issues related to corporate tax reform and the taxation of U.S. multinational corporations. S. 149, the Medical Device Access and Innovation Protection Act and H.R. 160, the Protect Medical Innovation Act, and issues related to repeal of the medical device tax. H.R. 880, the American Research & Competitiveness Act, S. 537. COMPETE Act, and issues related to the R&D tax credit. H.R. 2510 and S. 1660, to make permanent bonus depreciation. Issues related to bonus depreciation. H.R. 1430, to make permanent the CFC look-through rule. S. 1946, the Tax Relief Extension Act of 2015, as it relates to the R&D credit, bonus depreciation, and the CFC look-through rule. Issues related to corporate mergers.
Client expense: — · Firm income: $28,750
Matched citations: H.R. 1430
Protect Medical Innovation Act of 2015
2015 · third_quarter · Firm: THE NICKLES GROUP, LLC
Issues related to corporate tax reform and the taxation of U.S. multinational corporations. S. 149, the Medical Device Access and Innovation Protection Act and H.R. 160, the Protect Medical Innovation Act, and issues related to repeal of the medical device tax. H.R. 880, the American Research & Competitiveness Act, S. 537. COMPETE Act, and issues related to the R&D tax credit. H.R. 2510 and S. 1660, to make permanent bonus depreciation. Issues related to bonus depreciation. H.R. 1430, to make permanent the CFC look-through rule. S. 1946, the Tax Relief Extension Act of 2015, as it relates to the R&D credit, bonus depreciation, and the CFC look-through rule. Issues related to corporate mergers.
Client expense: — · Firm income: $28,750
Matched citations: H.R. 160
To amend the Internal Revenue Code of 1986 to modify and make permanent bonus depreciation.
2015 · third_quarter · Firm: THE NICKLES GROUP, LLC
Issues related to corporate tax reform and the taxation of U.S. multinational corporations. S. 149, the Medical Device Access and Innovation Protection Act and H.R. 160, the Protect Medical Innovation Act, and issues related to repeal of the medical device tax. H.R. 880, the American Research & Competitiveness Act, S. 537. COMPETE Act, and issues related to the R&D tax credit. H.R. 2510 and S. 1660, to make permanent bonus depreciation. Issues related to bonus depreciation. H.R. 1430, to make permanent the CFC look-through rule. S. 1946, the Tax Relief Extension Act of 2015, as it relates to the R&D credit, bonus depreciation, and the CFC look-through rule. Issues related to corporate mergers.
Client expense: — · Firm income: $28,750
Matched citations: H.R. 2510
Source: Senate LDA